Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 133 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: HDL Clear all
Completed Phase 2 Interventional

Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.

NCT00326326
View directory record Official record
Conditions
Dyslipidemia
Interventions
CP-778,875
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
31
States / cities
Anniston, Alabama • Huntsville, Alabama • Greenbrae, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 7, 2009 · Synced Oct 19, 2026, 2:31 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

NCT01047683
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
18
States / cities
Sacramento, California • Golden, Colorado • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 19, 2026, 2:31 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)

NCT00697203
View directory record Official record
Conditions
Dyslipidemia
Interventions
Placebo, Pravastatin, Dalcetrapib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
33
States / cities
Mobile, Alabama • Scottsdale, Arizona • Newark, Delaware + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 19, 2026, 2:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of a Nutritional Supplement on Metabolic Health

NCT02239198
View directory record Official record
Conditions
Cardiovascular Disease Prevention
Interventions
Nutrition bar
Other
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 19, 2026, 2:31 PM EDT
Completed Phase 1Phase 2 Interventional

Antihyperlipidemic Effects of Oyster Mushrooms

NCT00069524
View directory record Official record
Conditions
HIV Infections, Hyperlipidemia
Interventions
oyster mushroom
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2007 · Synced Oct 19, 2026, 2:31 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol

NCT01131299
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Placebo, Alpha cyclodextrin
Other · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 19, 2026, 2:31 PM EDT
Not listed Not applicable Interventional

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

NCT03135184
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia, HoFH
Interventions
HDL Therapeutics PDS-2 System
Device
Lead sponsor
HDL Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Oct 19, 2026, 2:31 PM EDT
Completed Phase 2 Interventional Results available

Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate

NCT01426438
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Niacin, Aspirin, Fenofibrate
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 19, 2026, 2:31 PM EDT
Completed Phase 2 Interventional

CER-001 Atherosclerosis Regression ACS Trial

NCT02484378
View directory record Official record
Conditions
Acute Coronary Syndromes
Interventions
CER-001, Placebo
Drug
Lead sponsor
Cerenis Therapeutics, SA
Industry
Eligibility
18 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
Huntsville, Alabama • San Diego, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Oct 19, 2026, 2:31 PM EDT
Withdrawn Phase 4 Interventional

Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia

NCT01180764
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Lovaza (Omega-3 acid ethyl esters), Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
35 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 19, 2026, 2:31 PM EDT
Completed Phase 2 Interventional

A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients

NCT01499420
View directory record Official record
Conditions
Stable Atherothrombotic Disease
Interventions
CSL112 (reconstituted high density lipoprotein), Placebo
Biological
Lead sponsor
CSL Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Chula Vista, California • Jacksonville, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 19, 2026, 2:31 PM EDT
Completed Not applicable Interventional

Effects of a Standardized Freeze-dried Grape Powder on High Density Lipoprotein (HDL) Function in Metabolic Syndrome

NCT02542176
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Freeze-dried Whole Grape Powder, Grape Powder Placebo
Other
Lead sponsor
University of Connecticut
Other
Eligibility
30 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Oct 19, 2026, 2:31 PM EDT
Completed Phase 3 Interventional Results available

High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly

NCT00127218
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Disease
Interventions
any statin, niacin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 19, 2026, 2:31 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Mendelian Reverse Cholesterol Transport Study

NCT01782027
View directory record Official record
Conditions
Cholesterol, HDL, Lipid Metabolism, Inborn Errors, Tangier Disease, LCAT Deficiency, Cholesteryl Ester Transfer Protein (CETP) Deficiency
Interventions
3H-cholesterol bound to albumin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 19, 2026, 2:31 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)

NCT00568594
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
APL180, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Oct 19, 2026, 2:31 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels

NCT00749788
View directory record Official record
Conditions
Dyslipidemia
Interventions
JTT-302, Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 19, 2026, 2:31 PM EDT
Completed Phase 1 Interventional

Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease

NCT01554800
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis
Interventions
ACP-501
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
30 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 19, 2026, 2:31 PM EDT
Terminated No phase listed Observational

Evaluation of High-Density Lipoprotein in Obesity Study

NCT00912236
View directory record Official record
Conditions
Obesity
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
20 Years to 80 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 19, 2026, 2:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers

NCT00984919
View directory record Official record
Conditions
Prostate Cancer
Interventions
high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry
Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
40 Years to 120 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 19, 2026, 2:31 PM EDT
Completed Not applicable Interventional

Effects of Peanut and Peanut Butter Consumption on Blood Lipids and Glycemic Control in Adults With Type 2 Diabetes

NCT00937222
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Peanuts and peanut butter
Dietary Supplement
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 19, 2026, 2:31 PM EDT
Completed Phase 3 Interventional

The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol

NCT00283335
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
gemfibrozil, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Up to 73 Years · Male only
Enrollment
2,531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 1999
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Oct 19, 2026, 2:31 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

HIV Antiretroviral Drugs and Metabolism

NCT00525239
View directory record Official record
Conditions
HIV Infections
Interventions
ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2011 · Synced Oct 19, 2026, 2:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Nutritional Supplement Effect on HDL Function

NCT04529174
View directory record Official record
Conditions
HDL
Interventions
CardioLux™HDL, Placebo
Dietary Supplement
Lead sponsor
Metagenics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 19, 2026, 2:31 PM EDT
Completed Phase 4 Interventional

Benefit of Elevation of HDL-C in Women

NCT01921010
View directory record Official record
Conditions
Cardiovascular Outcomes
Interventions
Niaspan, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 19, 2026, 2:31 PM EDT